CTM01 (7F11C7)

Antibody Name: CTM01
References: Baker, T.S., Bose, C.C., Caskey-Finney, H.M., King, D.J., Lawson, A.D.G., Lyons, A., Mountain, A., Owens, R.J., Rolfe, M.R., Sehdev, M., Yarranton, G.T. and Adair, J.R. "Humanization of an anti-mucin antibody for breast and ovarian cancer therapy" In "Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment" (1994) Ed. Ceriani, R.L., Plenum Press, New York pp61-82.
Banfield, M.J., King, D.J., Mountain, A. and Brady, R.L. "VL:VH Domain rotations in engineered antibodies: Crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs" Proteins (1997) 29:161-171.
Donor Antibody: mouse
Acceptor Antibody: Human IgG4P | k (IgG4P differs at S241P to allow complete disulphide bridge formation at the hinge)
Antigen: Polymorphic Epithelial Mucin (PEM) in Human Milk Fat globule (HMFG)
Laboratory: Celltech, UK
Design: CDR-grafting plus consensus residues at atypical positions in the human FRs.
Frameworks: VH EU | VL EU
CDRs: All 6 VH and VL, Kabat Definition.
Backmutations: Not stated.
Binding: "Similar" to mouse mAb as measured by competition binding assays. Second paper states it has "increased affinity (relative potency of 213%)".
Expression: transient CHO L761h and stable NS0 cells
Comment: Murine sequence not yet available.
Clinical Indication: Breast and ovarian cancers.

explanation of symbols and abbreviations

José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.